{"id":249997,"date":"2023-04-06T00:00:00","date_gmt":"2023-04-06T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/products\/research-reports\/report\/sptocg0014-2023-biopharma-major-depressive-disorder-dsm-v-special-topics\/"},"modified":"2026-04-26T23:26:15","modified_gmt":"2026-04-26T23:26:15","slug":"sptocg0014-2023-biopharma-major-depressive-disorder-dsm-v-special-topics-special-topics-comorbidities-in-major","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/sptocg0014-2023-biopharma-major-depressive-disorder-dsm-v-special-topics-special-topics-comorbidities-in-major\/","title":{"rendered":"Major Depressive Disorder (DSM-V) &#8211; Special Topics &#8211; Special Topics: Comorbidities in Major Depressive Disorder (US)"},"content":{"rendered":"<p>Psychiatric disorders such as anxiety, posttraumatic stress disorder (<abbr title=\"post-traumatic stress disorder\">PTSD<\/abbr>), and insomnia frequently coexist with major depressive disorder (<abbr title=\"major depressive disorder\">MDD<\/abbr>) and present treatment challenges to psychiatrists and primary care physicians (<abbr title=\"primary care physician\">PCP<\/abbr>s). Although some antidepressants are effective in managing <abbr title=\"major depressive disorder\">MDD<\/abbr> as well as a comorbid condition (e.g., selective serotonin reuptake inhibitors for <abbr title=\"major depressive disorder\">MDD<\/abbr> patients with comorbid anxiety), not all drug-treated patients fully respond to treatment. Treatment of <abbr title=\"major depressive disorder\">MDD<\/abbr> with a comorbid disorder presents opportunities for drug development and areas of clinical differentiation from existing antidepressants. Of note, Biogen \/ Sage Therapeutics\u2019 zuranolone has shown efficacy in its late-phase studies in reducing elevated anxiety in <abbr title=\"major depressive disorder\">MDD<\/abbr> patients. Janssen\u2019s seltorexant could be beneficial treating <abbr title=\"major depressive disorder\">MDD<\/abbr> patients with comorbid insomnia symptoms. The expected <abbr title=\"Food and Drug Administration\">FDA<\/abbr> approval of Lundbeck \/ Otsuka\u2019s Rexulti for <abbr title=\"post-traumatic stress disorder\">PTSD<\/abbr> could encourage physicians to prescribe the drug for <abbr title=\"major depressive disorder\">MDD<\/abbr> with comorbid <abbr title=\"post-traumatic stress disorder\">PTSD<\/abbr>. These therapies have the potential to alter treatment pathways for <abbr title=\"major depressive disorder\">MDD<\/abbr> patients with comorbid conditions.<\/p>\n<p><strong>QUESTIONS ANSWERED <\/strong><\/p>\n<ul class=\"round-bullets\">\n<li>Which comorbid disorders are most common in <abbr title=\"major depressive disorder\">MDD<\/abbr> patients? How do physicians treat <abbr title=\"major depressive disorder\">MDD<\/abbr> patients with comorbid anxiety, <abbr title=\"post-traumatic stress disorder\">PTSD<\/abbr>, or insomnia?<\/li>\n<li>What factors most influence physicians\u2019 choice of a pharmacotherapy for <abbr title=\"major depressive disorder\">MDD<\/abbr> patients with comorbid anxiety, <abbr title=\"post-traumatic stress disorder\">PTSD<\/abbr>, or insomnia?<\/li>\n<li>Which drug attributes should be at the forefront in the development of therapies to treat <abbr title=\"major depressive disorder\">MDD<\/abbr> patients with comorbid anxiety, <abbr title=\"post-traumatic stress disorder\">PTSD<\/abbr>, or insomnia?<\/li>\n<li>What are the physician-perceived advantages and disadvantages of zuranolone for managing <abbr title=\"major depressive disorder\">MDD<\/abbr> patients with a comorbid anxiety disorder and of seltorexant for managing <abbr title=\"major depressive disorder\">MDD<\/abbr> patients with comorbid insomnia? Where would these drugs, if launched, fit in the treatment algorithm for <abbr title=\"major depressive disorder\">MDD<\/abbr> patients with the respective comorbid disorder?<\/li>\n<li>How would Rexulti\u2019s additional <abbr title=\"Food and Drug Administration\">FDA<\/abbr> approval for <abbr title=\"post-traumatic stress disorder\">PTSD<\/abbr> impact physician prescribing of the drug to their <abbr title=\"major depressive disorder\">MDD<\/abbr> patients with comorbid <abbr title=\"post-traumatic stress disorder\">PTSD<\/abbr>?<\/li>\n<\/ul>\n<p><strong>PRODUCT DESCRIPTION <\/strong><\/p>\n<p>Clarivate\u2019s Special Topics reports assess key trends in dynamic disease areas. This report on comorbidities in <abbr title=\"major depressive disorder\">MDD<\/abbr> will help drug marketers and developers gain needed insight on physician-reported treatment dynamics, prescribing behavior, key challenges managing <abbr title=\"major depressive disorder\">MDD<\/abbr> patients with comorbidities such as anxiety disorder, <abbr title=\"post-traumatic stress disorder\">PTSD<\/abbr>, and insomnia, most important attributes for emerging therapies for these comorbid disorders, and physician perceptions of select emerging therapies that would benefit <abbr title=\"major depressive disorder\">MDD<\/abbr> patients with these comorbidities.<\/p>\n<p><strong>CONTENT HIGHLIGHTS<\/strong><\/p>\n<p><strong>Geographies:<\/strong> United States.<\/p>\n<p><strong>Primary research:<\/strong> Survey of 101 U.S. psychiatrists and <abbr title=\"primary care physician\">PCP<\/abbr>s.<\/p>\n<p><strong>Key drugs covered:<\/strong> Zuranolone (SAGE-217), Rexulti, seltorexant (JNJ-42847922), <abbr title=\"selective serotonin reuptake inhibitor\">SSRI<\/abbr>s, <abbr title=\"serotonin\/norepinephrine reuptake inhibitor\">SNRI<\/abbr>s, mixed serotonin modulators, atypical antipsychotics, <abbr title=\"N-methyl-D-aspartate\">NMDA<\/abbr> receptor antagonists, mood stabilizers, benzodiazepines, nonbenzodiazepine sedative-hypnotics, etc.<\/p>\n<p><strong>Key insights provided:<\/strong><\/p>\n<ul class=\"round-bullets\">\n<li>Patient characteristics.<\/li>\n<li>Physician treatment practices and physician insights on medical practice.<\/li>\n<li>Most important attributes for emerging therapies.<\/li>\n<li>Anticipated use of emerging therapies.<\/li>\n<\/ul>\n","protected":false},"template":"","class_list":["post-249997","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-major-depressive-disorder","biopharma-therapy-areas-psychiatry","biopharma-product-special-topics-other","biopharma-geography-us","biopharma-date-975"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/249997","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":1,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/249997\/revisions"}],"predecessor-version":[{"id":281673,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/249997\/revisions\/281673"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=249997"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}